drugset / Trial / NCT01783821
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
Phase 2
Completed
61 enrolled
Mayo Clinic
Beth Israel Deaconess Medical Center · collabNational Center for Research Resources (NCRR) · collabStanford University · collabUniversity of Arizona · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent pulmonary injury when administered early in hospital course to the patients at risk for developing acute respiratory distress syndrome (ARDS). The FDA has approved many uses for budesonide and formoterol, including asthma and chronic obstructive pulmonary disease (COPD), but the use of these two drugs is experimental for ARDS.
Timeline
- Start
- 2013-07
- Primary completion
- 2015-07
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 0.5 mg | Inhaled |
| Subject | Formoterol | Other / unclassified | 20 ug | Inhaled |